Mechanism of Action
GIP Potentiation via Neural Pathway
Xenin-25 does not directly stimulate insulin secretion but potentiates GIP-induced insulin release through activation of cholinergic neurons in the pancreatic-intestinal neural circuit. Xenin activates neurotensin receptors (NTS1, NTS2) on enteric nervous system neurons, increasing local acetylcholine release. This cholinergic signal amplifies GIP receptor signaling on beta cells, restoring GIP responsiveness that is characteristically blunted in type 2 diabetes.
Pancreatic Secretion
Beyond insulin potentiation, xenin-25 is a potent stimulator of pancreatic exocrine secretion (enzyme and bicarbonate output) through NTS receptor-mediated vagal activation. This pancreatic secretagogue effect prompted early research into xenin as an alternative to secretin for pancreatic function testing. Xenin also slows gastric emptying and reduces food intake, consistent with its incretin family membership.
Research Summary
GIP Responsiveness in T2D
HumanA key xenin discovery is that type 2 diabetic patients with impaired GIP-stimulated insulin secretion show restored insulin response when GIP is infused together with xenin, but not with GIP alone. This suggests xenin could overcome the GIP resistance seen in T2D through its neural amplification pathway, opening novel T2D treatment strategies distinct from direct GLP-1 or GIP receptor agonism.
Incretin Effect Enhancement
HumanXenin infusion in healthy humans potentiates GIP-stimulated insulin secretion dose-dependently. The effect requires intact cholinergic signaling, as atropine (muscarinic blocker) abolishes xenin potentiation of GIP. These human pharmacology studies establish the xenin-cholinergic-GIP axis as a validated pathway with therapeutic implications.
Appetite and Weight
AnimalCentral and peripheral xenin administration reduces food intake in rodents, with effects on gastric emptying delay and satiety signaling through the NTS receptor system. These properties align with xenin's classification as an incretin-family satiety peptide, though weight loss effects have been modest in studied models.
Calculate your Xenin-25 dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| GIP potentiation research | 4-12 pmol/kg/min | Co-infusion with GIP x 30-120 min | Intravenous |
| Pancreatic secretion test | 10-100 pmol/kg/min | Single infusion | Intravenous |
Xenin research requires IV infusion due to the short plasma half-life. Stable xenin analogs with extended activity are under development for potential clinical applications.
Interactions
Safety Profile
Xenin infusion in human studies has been well tolerated. Nausea and abdominal cramping have been reported at higher doses, consistent with pancreatic and GI stimulation. Transient hypotension via vasodilatory NTS receptor activity was observed at high doses. No significant adverse events were reported in Phase I studies. The short half-life limits duration of any pharmacological effects.
References
- [1]Feurle GE, et al. Xenin, a phylogenetically conserved peptide induced by fat ingestion and secreted from gastric epithelial cells. Regul Pept. 1997.
- [2]Kunkel D, et al. Xenin potentiates the effects of glucose-dependent insulinotropic polypeptide in subjects with impaired glucose tolerance. Diabetes. 2011;60(7):1793-1800.
- [3]Holst JJ, Veedfald S. The physiology and pharmacology of incretin hormones. Pharmacol Rev. 2023.